Allergy Therapeutics begins Phase II trial of grass pollen allergy vaccine

Allergy Therapeutics plc (LSE:AGY) started the Phase II G205 trial of Pollinex Quattro Grass in about 440 patients with grass pollen allergy. The company told BioCentury it expects data in 2H18.

The double-blind, placebo-controlled, European trial will evaluate 4 different maximum doses, ranging from 300 to 8000 standardized unit/mL. The primary endpoint is dose response as measured by post-treatment total symptom score (TSS) following conjunctival provocation test (CPT) Secondary endpoints will evaluate safety, change from baseline to post-treatment TSS following CPT and number of additional allergen concentration steps required to elicit a positive CPT...